Open Studies

OVARIAN

 
BGOG-ov-50

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)

Sponsor: Novocure

Participating sites:

  • CHU UCL Namur, site Sainte Elisabeth, Namur
  • UZ Gent, Gent
  • UZ Leuven, Leuven
  • CHU Ambroise Paré, Mons
  • AZ Maria Middelares, Gent
  • CHU Dinant Godinne, Yvoir
  • Grand Hôpital de Charleroi, Charleroi
  • Imelda ziekenhuis, Bonheiden
  • CHU UCL St-Luc, Bruxelles

Learn More ->

BGOG-ov-46

Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

Sponsor: AstraZeneca

Participating sites:

  • AZ Nikolaas, St-Niklaas
  • AZ Damiaan, Oostende
  • OLV Aalst, Aalst
  • UZ Leuven, Leuven
  • CHU UCL Namur, site Sainte Elisabeth, Namur

Learn More ->

BGOG-ov-44

A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Sponsor: GSK/Tesaro

Participating sites:

  • UZ Leuven, Leuven
  • AZ Sint-Jan Brugge, Brugge
  • CHU St. Pierre, Bruxelles
  • AZ Klina, Brasschaat

Learn More ->

BGOG-ov-43

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • AZ Maria Middelares, Gent
  • Imelda Ziekenhuis, Bonheiden
  • Grand Hôpital de Charleroi, Charleroi
  • Hôpital de Libramont, Libramont
  • UZ Leuven, Leuven
  • UZ Gent, Gent
  • Jessa Ziekenhuis, Hasselt
  • CHU de Liège, site Sart Tilman, Liège
  • UZ Antwerpen, Antwerpen
  • CHU UCL St-Luc, Bruxelles

Learn More ->

BGOG-ov-41

A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months

Sponsor: Grupo Español de Investigación en Cáncer de Ovario (GEICO)

Participating sites:

  • UZ Leuven, Leuven
  • CHU Ambroise Paré, Mons
  • CHU UCL Namur, site Sainte Elisabeth, Namur
  • CHU UCL St. Luc, Bruxelles
  • Grand Hôpital de Charleroi, Charleroi
  • CHU de Liège, site Sart Tilman, Liège

Learn More ->

BGOG-ov-55

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Sponsor: ImmunoGen

Participating sites:

  • Hôpital de Libramont, Libramont
  • UZ Leuven, Leuven
  • OLV Aalst, Aalst
  • UZ Antwerpen, Antwerpen
  • AZ Sint Lucas, Gent
  • AZ Klina, Roeselare

Learn More ->

BGOG-ov-38

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.

Learn More ->

ENDOMETRIUM

 
BGOG-en-6

A Phase 3, Randomized, Double-blind, Multicenter Study Comparing TSR-042 plus Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin plus Placebo in Patients with Recurrent or Advanced Endometrial Cancer Who Had Received no Previous Systemic Anticancer therapy for Advanced or Metastatic Disease

Sponsor: GSK/Tesaro

Participating sites:

  • UZ Leuven, Leuven
  • CHU de Liège, site Sart Tilman, Liège
  • OLV Aalst, Aalst

Learn More ->

BGOG-en-9

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • UZ Leuven, Leuven
  • CHU UCL St-Luc, Bruxelles
  • UZ Antwerpen, Antwerpen
  • AZ Maria Middelares, Gent
  • AZ Delta, Roeselare

Learn More ->

BGOG-en-10

Randomized, Multi-Center, Double Blind Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

Sponsor:  AstraZeneca

Participating sites:

  • UZ Leuven, Leuven
  • UZ Gent, Gent
  • CHU UCL St-Luc, Bruxelles
  • Hôpital de Libramont, Libramont
  • AZ Groeninge, Kortrijk
  • AZ Sint Jan Brugge, Brugge
  • Grand Hôpital de Charleroi, Charleroi
  • Clinique CHC Montlégia, Liège
  • Jessa Ziekenhuis, Hasselt

Learn More ->

BGOG-EN-5

An Investigator-Sponsored Randomized Phase III Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer 

Learn More ->

VULVAR

 
BGOG-v-1

Groningen International Study on Sentinel Lymph Nodes in Vulvar Cancer II – An observational study

Learn More ->

CERVIX

 
BGOG-cx-8

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® ®-TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer

Sponsor: Genmab

Participating sites:

  • UZ Leuven, Leuven
  • CHU de Liège, site Sart Tilman, Liège
  • UZ Antwerpen, Antwerpen
  • CHU UCL St-Luc, Bruxelles
  • Grand Hôpital de Charleroi, Charleroi
  • CHU UCL St-Luc, Bruxelles
  • AZ Sint-Jan Brugge, Brugge
  • UZ Gent, Gent
  • Hôpital de Libramont, Libramont

Learn More ->

BGOG-cx-11

A randomized, Phase 3, double-blind study of radiochemotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • AZ Sint-Lucas, Gent
  • UZ Leuven, Leuven
  • GZA campus Sint-Augustinus, Antwerpen
  • OLV Aalst, Aalst
  • CHU Ambroise Paré, Mons
  • UZA, Antwerpen

Learn More ->

BGOG-cx-2B

A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer.

Learn More ->

BGOG-cx3

Prospective randomized Phase II trial comparing doxorubicin alone versus atezolizumab alone versus doxorubicin and atezolizumab in recurrent cervical cancer.

Learn More ->